Comprehensive Overview

As a biotechnology company at the clinical trial stage, the Group is committed to developing novel vaccines and biotherapeutic candidate products for infectious diseases, cancer and autoimmune diseases. The core product is SCB-2019 (CpG 1018 plus aluminum adjuvant), which mainly responds to the COVID-19 outbreak. It is expected to submit conditional regulatory approval applications to the EMA, the National Drug Administration and WHO in the fourth quarter of this year. The product can be launched as early as the end of this year; the other core product is SCB-808, which is used to treat rheumatic diseases.

Risk Factors

A large number of vaccine manufacturers, academic institutions and other organizations are developing candidate COVID-19 vaccines, and there are many potential opponents; even if the group successfully produces a vaccine against COVID-19, it will still need to invest a lot of resources to expand and develop it. Regulatory requirements of local institutions, including EMA, National Drug Administration, WHO, etc., have changed as the virus evolves, and may affect the progress of the group in SCB-2019 (CpG 1018 plus aluminum adjuvant). Furthermore, the group generated net debt during the historical record period. As of the end of April this year, the net debt amount reached 1,883.5 billion yuan, which may put the group at risk of liquidity.